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to demonstrate the value of interventions and support health tech-
nology assessment (HTA). Objective: The objective of this work was to
analyze trends regarding PROs in Latin America (LatAm), highlight
challenges in the application of PROs in this region, and suggest
solutions. Methods: A team of researchers with expertise in PROs
conducted a nonsystematic PubMed literature search pertaining to the
use of PROs in LatAm. The experts also drew on their experience
working with PROs to assess the application of PROs in LatAm.
Results: The literature search yielded more than 4000 publications,
with an increasing publication rate in recent years. PROs are being
used in LatAm in various study types: instrument validation, phase III
international clinical trials, health service research. A large Inter-
American Development Bank study demonstrates the growing impor-
tance of PROs in the region. The growth in local value sets for the
EuroQol ﬁve-dimensional questionnaire in LatAm reﬂects the regionalee front matter Copyright & 2015, International S
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ndence to: Randall Winnette, Novartis Pharmaceuemergence of HTA systems. Operational challenges relate to
ensuring the use of good-quality questionnaires that, at a mini-
mum, have undergone appropriate cultural adaptation and ideally
have established psychometric properties. Conclusions: PROs are
increasingly important in LatAm. Future efforts should aim to
strengthen the operational and research infrastructure around PROs
in the region. Innovation should be encouraged, including studying
alternative methods of eliciting health utilities for economic evaluation.
A wider scope around PRO uses for decision making by HTA bodies is an
international trend with potential positive prospects in LatAm.
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Patient-reported outcomes (PROs) provide important insight into
the patient experience with a disease or treatment that may
facilitate health care decision making by prescribers and payers,
as well as patients. Such data are collected directly from the
patient, without interpretation from others [1], through the use of
patient-reported outcome measures (PROMs), also referred to as
instruments, questionnaires, or scales. In recent years, the com-
petitive global marketplace has increasingly acknowledged the
usefulness of PRO data to support labeling, communication
strategies, and value messages.
PRO data may also demonstrate value for the purposes of
health technology assessment (HTA). HTA provides quantitative
estimates of the efﬁcacy and safety of new drug entities as well
as insight into the cost-effectiveness of therapies. Such data are
used to guide reimbursement and market access decisions. There
is growing recognition that when balancing costs and effective-
ness, it is important to include inputs reﬂecting the patients’voice. As such, the patient’s voice, as evaluated by PROMs in
pharmaceutical interventional studies, is increasingly taken into
consideration in HTA evaluations in both the European Union
and the United States [2].
In Latin America (LatAm), HTA systems are emerging and
consolidating. Currently, there are three main agencies that
oversee HTA at a national level, along with a number of other
private and public agencies. Given constrained health care
budgets, countries increasingly require a formal evaluation of
new health care technology to assess value for money. Therefore,
regulatory approval of a new product must be accompanied by
data that will demonstrate the value of the product in order to
secure reimbursement [3].
Integrating PROMs into clinical research and seeing that the
resulting data are used appropriately in the health care decision-
making process is not without challenges. There are various
challenges in the integration of PROMs in multiregional trials,
with some concerns speciﬁc to LatAm such as cultural impact/
literacy level and technology infrastructure [4]. In regard toociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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may not be readily available for use in cost-effectiveness evalua-
tion. Also, the value of PRO data may not be recognized for
individual and population decision making.
The intent of this article was to assess the progress of
integrating PROs into clinical research and decision making in
LatAm, identify the challenges that may currently inhibit the
integration of PROs in these practices, and propose potential
solutions.Methods
Three pharmaceutical representatives with expertise in PRO
development and implementation in clinical studies, one PRO
expert, and one LatAm researcher with expertise in health-
related quality of life reviewed the PRO research and applications
landscape in LatAm clinical trials and health services research.
An effort was made to identify issues that are applicable across
therapeutic areas. The relevant literature was identiﬁed through
a PubMed literature search using the names of LatAm countries
as MeSH terms, or in title/abstract, and combining those terms
with the MeSH term “quality of life” or “quality of life” in title/Table 1 – PubMed search terms and results (October 25
Search/date Search terms
No. 1 “quality of life” in
title, abstract, or MeSH
term
((“argentina”[MeSH Terms] OR “argentin
Terms] OR “brazil”[All Fields]) OR (“me
Fields]) OR (“chile”[MeSH Terms] OR “
(“venezuela"[MeSH Terms] OR “venezu
Terms] OR “peru”[All Fields]) OR (“colo
“colombia"[All Fields]) OR (“bolivia”[M
OR (“ecuador"[MeSH Terms] OR “ecua
(“uruguay"[MeSH Terms] OR “uruguay
Terms] OR (“costa”[All Fields] AND “ri
Fields]) OR (“guatemala”[MeSH Terms
(“panama”[MeSH Terms] OR “panama
(“qualityþofþlife”[tiab] OR “quality of
No. 2 “quality of life” in title
or MeSH term
((“argentina”[MeSH Terms] OR “argentin
Terms] OR “brazil”[All Fields]) OR (“me
Fields]) OR (“chile”[MeSH Terms] OR “
(“venezuela"[MeSH Terms] OR “venezu
Terms] OR “peru”[All Fields]) OR (“colo
“colombia"[All Fields]) OR (“bolivia"[M
OR (“ecuador"[MeSH Terms] OR “ecua
(“uruguay"[MeSH Terms] OR “uruguay
Terms] OR (“costa”[All Fields] AND “ri
Fields]) OR (“guatemala"[MeSH Terms
(“panama”[MeSH Terms] OR “panama
(“qualityþofþlife”[ti] OR “quality of lif
No. 3— Validation studies ((“argentina”[MeSH Terms] OR “argentin
Terms] OR “brazil”[All Fields]) OR (“me
Fields]) OR (“chile”[MeSH Terms] OR “
(“venezuela"[MeSH Terms] OR “venezu
Terms] OR “peru”[All Fields]) OR (“colo
“colombia"[All Fields]) OR (“bolivia”[M
OR (“ecuador”[MeSH Terms] OR “ecua
(“uruguay”[MeSH Terms] OR “Uruguay
Terms] OR (“costa”[All Fields] AND “ri
Fields]) OR (“guatemala”[MeSH Terms
(“panama”[MeSH Terms] OR “panama
(“qualityþofþlife”[tiab] OR “quality of l
Studies” [Publication Type]abstract (Table 1). The search included all articles from 1974
through October 25, 2013; however, few studies were identiﬁed
before 1990. No attempt was made to perform a systematic
review of this literature. Instead, the present review was used
to complement the expertise and qualitative discussion of the
authors along with feedback gathered at a recent seminar at
which the authors engaged health care decision makers from
different LatAm countries.Results
Research and Operational Landscape for PROs in Latin
America
Research landscape
The initial search (search no. 1) of PubMed identiﬁed 4000
publications using the term “quality of life” in the title, abstract,
or MeSH term, combined with relevant terms for LatAm countries
(Table 1 and Fig. 1). When limiting the search to only the title or
the MeSH term, 2500 articles were found (Table 1, search no. 2).
When reviewing the results by date of publication, it was found
that the number of publications per year has steadily increased, 2013).
Number of PubMed hits
(1974–October 25, 2013)
a”[All Fields]) OR (“brazil”[MeSH
xico”[MeSH Terms] OR “mexico”[All
chile”[All Fields]) OR
ela”[All Fields]) OR (“peru”[MeSH
mbia"[MeSH Terms] OR
eSH Terms] OR “bolivia"[All Fields])
dor"[All Fields]) OR
”[All Fields]) OR (“costa rica”[MeSH
ca”[All Fields]) OR “costa rica”[All
] OR “guatemala"[All Fields]) OR
”[All Fields])) AND
life”[MeSH Terms])
4332
a”[All Fields]) OR (“brazil”[MeSH
xico”[MeSH Terms] OR “mexico”[All
chile”[All Fields]) OR
ela"[All Fields]) OR (“peru”[MeSH
mbia"[MeSH Terms] OR
eSH Terms] OR “bolivia"[All Fields])
dor"[All Fields]) OR
"[All Fields]) OR (“costa rica”[MeSH
ca”[All Fields]) OR “costa rica”[All
] OR “guatemala"[All Fields]) OR
”[All Fields])) AND
e”[MeSH Terms])
2554
a”[All Fields]) OR (“brazil”[MeSH
xico”[MeSH Terms] OR “mexico”[All
chile”[All Fields]) OR
ela"[All Fields]) OR (“peru”[MeSH
mbia”[MeSH Terms] OR
eSH Terms] OR “bolivia”[All Fields])
dor”[All Fields]) OR
”[All Fields]) OR (“costa rica”[MeSH
ca”[All Fields]) OR “costa rica”[All
] OR “guatemala”[All Fields]) OR
”[All Fields])) AND
ife”[MeSH Terms]) AND “Validation
211
Fig. 1 – Number of PubMed hits (search no. 1).* *The search covered all results from 1974 through October 25, 2013; however,
few studies were identiﬁed before 1990.
V A L U E I N H E A L T H R E G I O N A L I S S U E S 8 C ( 2 0 1 5 ) 4 9 – 5 5 51since the early 2000s, showing a clear increase in interest in this
area of research.
The research on PROs in LatAm was grouped into the follow-
ing ﬁve categories:1. PROM content and psychometric validation studies: Valida-
tion of PROMs is an active area of development in LatAm
where many PROMs are being developed or translated and
culturally validated for use in the LatAm population.2. Clinical research: PROs are currently included as part of
large phase III multinational studies assessing pharma-
ceutical products. These studies are generally published in
international journals with aggregated results, and the
results for LatAm study participants are not directly cap-
tured in bibliographic searches as stand-alone publi-
cations.3. PROs in regional or local research, including clinical trials and
other prospective studies (international, regional, or local): For
example, PROGIS [5] was a prospective observational study
that investigated the evolution of gastrointestinal PROs in
kidney transplant recipients. A battery of PROMs related to
gastrointestinal health (Gastrointestinal Symptom Rating
Scale), Gastrointestinal Quality of Life Index) and the Psycho-
logical General Well-being index were measured at baseline
and 4 to 6 weeks. Sites from Argentina and Chile participated
in the study.4. PROs in other health services research studies: Cross-
sectional studies in different groups, for example, health-
related quality of life in primary care settings [6], in patients
with multiple sclerosis [7,8], explanatory models for patient
PROs [9], caregiver PROs [10], and PROs in prospective cohort
studies [11].5. PROs in population-based studies: At the population level,
generic PROMs, such as the EuroQol ﬁve-dimensional ques-
tionnaire (EQ-5D), are frequently used to monitor or establish
reference values for self-perceived health, complementing
the traditional morbidity and mortality indicators. The EQ-5D
was used in the 2003 Argentinean National Survey on
Risk Factors [12] (the short- form 36 health survey was also
used) and in a 2007 survey of 19 LatAm countries sponsored
by the Inter-American Development Bank [13]. Use of the
EQ-5D was used in the 2014 Chilean National Quality of Life
Survey.Operational landscape
Two unique aspects of PROMs are that they cannot be queried or
corrected retrospectively and must be completed in a patient’s
native language or the language in which they converse on a
day-to-day basis [2,4]. PRO data must be collected in a stand-
ardized manner so that the data are internally consistent and
coherent for the purpose of analysis. A well-designed PROM will
minimize bias, whereas a poorly designed PROM results in poor
data quality that cannot be compensated for later in clinical
trials.
As shown in the previous section, PROs are used in LatAm in
diverse situations. The next section focuses on general recom-
mendations to take into account when deploying studies
containing PROMs.
Planning
Several elements are of critical importance in planning for the
implementation of PROs, especially translated PROMs, within a
clinical trial:1. Which PROMs are to be included?
2. Is the context of use appropriate?
3. Where are the investigational sites located?
4. Will the patient complete the PROMs on paper or using an
electronic device?
5. Do appropriately translated version(s) of PROM(s) exist or
must they be newly created?
6. If translated versions exist, do they meet current regulatory
standards?
7. When will translations be needed for ethics review?
Each of the items listed above should be established as early
in the implementation process as is feasible to ensure the timely
inclusion of PROMs in the trial.
Creating Validated Translations
The 2009 Food and Drug Administration Guidance on Patient-
Reported Outcomes states that the sponsor should be prepared to
demonstrate that sufﬁcient care was taken to ensure that
translated PROMs are conceptually equivalent to the original
version [1]. Speciﬁcally, the agency intends to review the
following:
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for populations that will use them in the trial;2. The description of patient testing, language- or culture-
speciﬁc concerns, and rationale for decisions made to create
new versions;3. Copies of translated or adapted versions; and
4. Evidence that content validity and other measurement prop-
erties are comparable between the original and new [trans-
lated] measures.
To meet these guidelines, sponsors are advised to develop
new translations according to the ISPOR Good Translation
Practices [14]. The reiterative translation and patient testing
process is shown in Fig. 2. Evidence that this linguistic
validation process was used to create new translations, includ-
ing full harmonization and cognitive debrieﬁng of the trans-
lation, can be used to support the assertion that the content
validity and other measurement properties of the translations
are comparable to those of the original PROM. A report
describing the harmonization and pilot-testing phases of the
translation development as well as certiﬁcations detailing the
methodology used to create the translated version(s) shouldFig. 2 – Linguistic valiaccompany all translations. Any translation lacking such
detailed documentation risks being rejected by regulatory
authorities.
Allowing Sufﬁcient Time to Create the New Translations Is
Essential
Because PROMs are most often developed in English, authors
should assess the translatability of the new questionnaire and
whether the concepts included are appropriate to a range of
cultures. Typical areas that should be scrutinized include the
following:1.daReferences to country- or religion-speciﬁc holidays such as
Halloween and Christmas;2. References to sports and leisure activities such as baseball,
golf, and football;3. The use of AM/PM instead of a 24-hour clock;
4. References to health care resources;
5. Idiomatic expressions;
6. Measurements of distance (English vs metric); and
7. Topics that may be culturally sensitive (e.g., erectile dysfunc-
tion and use of birth control techniques).tion process.
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will require cultural adaptation or even need to be excluded from
the measure entirely. Such cultural adaptation and psychometric
validation are active areas of research in LatAm, as shown by the
amount of work published and also intramural activities of
sponsors preparing PROMs for use in multinational clinical trials
that include LatAm countries.
Methods of Administration
Most of the validated PROMs were initially designed for paper
administration. As the industry moves increasingly toward elec-
tronic administration of PROs (ePRO), several problems may
result from failure to plan for ePRO administration early in the
study implementation process. For example:1. Learning that existing translations are worded for paper and
not for ePRO or Interactive Voice Response System
administration;2. Selecting an inappropriate ePRO tool for administering the
PROM (e.g., one in which the translation may be too long to ﬁt
on the device screens); and3. Discovering that the local infrastructure cannot support the
device.
In LatAm, PROMs are most commonly administered via paper.
The increasing presence of health information technologies and
mobile devices, however, can facilitate the conduct of studies on
electronic platforms, which have been shown to increase data
quality. Use of ePRO should be explored both in countries with
more modern communication infrastructures and, when possi-
ble, in countries that are still developing such technology.
Other Concerns Speciﬁc to LatAm1. Language: Although Spanish is the primary language spoken in
LatAm, there are other countries where Portuguese or French is
the dominant language. It is also important to consider the
variety of dialects in each country. Although PROMs should be
appropriately translated and validated for use in the speciﬁc
target population, in some studies, in the absence of version(s)
appropriate for the country, PROMs are implemented by using
the closest language-equivalent version. For example, the Work
Productivity and Activity Impairment Questionnaire for Asthma
exists in Spanish for Chile. No version, however, is currently
available for Argentina. If an Argentinian version is needed for a
clinical trial being run in that country, one solution would be to
pilot test the Chilean version in Argentina [14]. Other
approaches may exist and should be discussed with a linguistic
validation specialist. Overall, the practice of using a PROM
developed for a speciﬁc target country in a country where it
has not been pilot tested should be avoided or minimized
because its use may compromise the concept validity of the
translated PROM and result in problems in pooling data.2. Literacy: Literacy levels vary greatly throughout LatAm, espe-
cially between urban and rural settings. Before implementing
a study, the literacy level of the target population should be
carefully assessed. It should be noted that even in regions
with high literacy, such as urban areas, some groups may
have difﬁculty understanding and answering PROMs (e.g.,
rural migrant communities), especially in studies that
approach patients during usual care. In these cases, the
likelihood of success may be addressed through including a
pilot study and success will be largely dependent on appro-
priate study coordinator training.3. Cultural taboo: Varying attitudes among cultures toward
conditions with a particular social stigma, such as obesity orAIDS, may affect PRO data. For example, fear of stigma and
discrimination associated with HIV in parts of the world
prevent patients from reporting symptoms and seeking treat-
ment. Also, reporting of taboo subjects such as income and
sexual behaviors may be problematic in some societies.4. Ethics review: Large phase III studies that include PROs are
being conducted in LatAm. Although the ethics review cover-
ing these studies seems to appropriately address the risk-
beneﬁt of such questionnaires, the use of PROMs in observa-
tional studies can sometimes be challenged. Some ethics
committees may have the perception that including PROMs
makes a study interventional, and lack of experience of the
less specialized centers can make these reviews more cum-
bersome than needed. More education and engagement is
needed to address the gaps in understanding regarding the
use of PROMs in observational research.
PROs and Health care Decision Making in Latin America
HTA in Latin America
Health technology assessment (HTA) is important across differ-
ent health systems due to its potential to promote the rational
use of health interventions, contribute to the allocation of scarce
health care resources, and inform the impact of additional
investments in health through health expenditures.
In LatAm, HTA systems ﬁrst emerged in México in the 1980s
and have steadily grown in prominence, especially over the last
decade, with many being recognized as part of the International
Network of Agencies for Health Technology Assessment
(INAHTA). A summary of the key HTA institutions and trends
in LatAM is provided below:1. Argentina: The Instituto de Eﬁcacia Clinica y Sanitaria [15], a
nongovernmental HTA institute, was established in 2001. It is
part of INAHTA [16] and plays an advisory role in the creation
and consolidation of other HTA institutions in the region. HTA
regulations appeared in the Superintendencia de Servicios de
Salud, the government body in charge of creating and updat-
ing the social security compulsory coverage package. These
regulations, however, were not fully implemented, and the
country did not advance toward an established HTA system.
In 2009, the National Health Technology Assessment Coordi-
nating Unit was created in the Ministry of Health. This is the
HTA National Coordinating Unit that is also part of INAHTA.2. Brazil: The Department of Science and Technology of the
Ministry of Health incorporated HTA into its remit in the year
2000 (Department of Science and Technology is a member of
INAHTA). The National Commission for the Incorporation of
Technology was established in 2011 and formally requires
economic evaluation and budget impact models to assess
pharmaceutical products. Brazil also introduced Rede Brasi-
leira de Avaliação de Tecnologias em Saúde [17] in 2009, a
resource to produce and disseminate HTA studies and
enhance health care decision making.3. Chile: The Unit for Health Technology Assessment [18] was
established in 1997 as the HTA unit in the Ministry of Health
of Chile and was the ﬁrst LatAm institution to be recognized
as part of INAHTA. Guidelines for Economic Evaluation were
issued in 2012, and it is expected that HTA will gain prom-
inence in Chilean health care decision making in the short or
mid-term.4. Colombia: After several failed attempts to reform the system,
the Instituto de Evaluation de Tecnolgias Sanitaria [19] was
created in 2011 and launched in 2012 as a national health
technology agency to advice on the formulation and update of
the health beneﬁts package.
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de Salubridad General) [20] issued a regulation that required
economic evaluation to assess the incorporation of products
into the National Formulary. A government agency (Centro
Nacional de Excelencia Tecnolgica en Salud) [21] was created
in 2004, which is part of INAHTA and has a more active role in
assessing medical technology. Around the same time, in
response to a regulation by the National Health Council,
companies began submitting economic evaluations, a trend
that has steadily increased in recent years. In 2008, Guidelines
for Economic Evaluation were issued, with a subsequent
update in 2011. These are the ﬁrst guidelines acknowledging
an explicit threshold for cost-effectiveness.6. Other initiatives: Worth noting are initiatives to strengthen
the regional HTA network. An Andean Network of HTA was
established in 2006 [22]. In 2010, redETSA, a regional network
of HTA institutions, was proposed and launched via a Pan
American Health Organization–led initiative. In 2012, the
LatAM HTA community achieved a historic landmark when
all state members signed a Pan American Health Organization
resolution endorsing HTA in the region.
HTA and PROs
PROs have two main roles in HTA. In the current climate, the
main focus is on health utilities that provide information for the
valuation of health interventions in economic evaluations. PROs
can also enter the decision-making process directly, as docu-
mentation of the burden of disease or value of an intervention.
Governments and other organizations that ﬁnance health care
interventions are making increasing use of economic evaluation as
a tool to support prioritization of health care expenditure. In
general, cost-effectiveness and cost-utility interventions are
favored over cost-beneﬁt analyses. To perform a cost-utility
analysis using differential quality-adjusted life-years, health valu-
ations for all the health states in the study are needed on a scale of
0 to 1 (0 ¼ death, 1 ¼ full health). There are several options for the
valuation of health states including direct elicitation (with time
trade-off or visual analogue scale), use of generic utility measures
such as the EQ-5D, or mapping from generic or disease-speciﬁc
health-related quality-of-life measures.
The EQ-5D, a PROM, is one of the most prominent and widely
used measures for the generation of health utility values. There
are several value sets available for all the health states generated
by the EQ-5D, and these values can be applied directly to health
status when measured as EQ-5D proﬁles. In LatAm, there are
currently three countries with local EQ-5D value sets: Argentina
[23], Brazil [24], and Chile [25]. A “universal” set is also available,
from work that derived the health state valuation for Hispanics
living in the United States [26].
PROs could also have a role in individual decision making. For
example, PROs are mentioned in a clinical guideline for the
treatment of posttraumatic urethra stenosis in males, issued by
the Instituto Mexicano de Seguridad Social [27], the biggest
insurer in México. This guideline recommends use of the auto-
control of urine ﬂow scale, a PRO, together with clinical explora-
tion “under clinical suspicion” of a case [28]. This PRO is also
recommended to guide clinical decisions.Discussion
PROs are essential for demonstrating unmet medical need and
the value of interventions in health care. PROs are increasingly
used in different regions of the world, and LatAm is no exception
to these trends. The high number of publications currently in the
public domain that focus on LatAm and include quality of life inthe title or abstract is evidence of this trend. It is worth noting
that in the absence of the MeSH term “Patient Reported Out-
comes,” the MeSH term “quality of life”was used (as a MeSH term
and for title/abstract). Thus, this search likely underreports the
level of PRO research that exists in this ﬁeld.
PROs are in use in various study contexts throughout LatAm,
including large phase III international studies, observational
research, PROM validation, and population surveys. It is impor-
tant to continue to monitor these trends, and a systematic review
of the literature of PROs in LatAm is recommended. Studies about
comparative health status, like the one developed by the Inter-
American Development Bank, should be encouraged, as well as
population surveys taking advantage of PROs. It is also important
to continue to increase the research capacity in the ﬁeld; a
mapping of experts and available trainings would be beneﬁcial.
Innovative designs should also be put forward. For example, in
the PROGIS study, data were used to psychometrically validate
the PROMs for Argentina and Chile [29]. This project added to the
existing validation literature and also provided information on
the test-retest reliability of the questionnaires, which had not
been previously explored.
Having a suitable, culturally adapted, and psychometrically
validated PROM is the ideal situation. Investigators working in
hospitals and other health care environments have an important
role in promoting this best research practice. Investigators should
also have a central role in the development of any new PROM
that will be deployed internationally. Such investigators should
be mindful of key operational considerations, such as the need to
ensure that PROMs used in LatAm trials have undergone sound
cultural adaptation and translation. In addition, psychometric
properties of questionnaires in LatAm settings, especially in
diverse disease groups, need to be further explored and docu-
mented. Locally developed PROs may also be a reality; however,
these should be applied only after appropriate consideration has
been given to existing PROMs and the need for a novel measure
has been fully established. It is also necessary to ensure consis-
tent administration of PROMs and full understanding by patients
as to the purpose of and their part in the study. This can be
especially challenging in environments with high illiteracy or
functional illiteracy, or even in urban environments in which
literacy is high but the population is generally unable to com-
prehend the aim of the questionnaire or study.
Sponsors should be mindful of the issues involved in procur-
ing or developing appropriately validated translations for inclu-
sion in a clinical trial. Successful execution requires both
planning and research. It is important to establish the methods
by which new or existing translations are produced and to ensure
that they are culturally appropriate for the target population. In
addition, determining the mode of administration before initiat-
ing the translations can save precious time and reduce costs.
With the growth of the telecommunication infrastructure world-
wide, opportunities are emerging to conduct studies using elec-
tronic platforms such as cell phones or other mobile devices.
PROMs, however, must be fully validated for use on these plat-
forms before being deployed in a study [30]. Study teams must be
mindful of these issues and employ study personnel with the
skills to collect evaluable quality PRO data. All study methods
should be fully validated by experts in the ﬁeld before full
implementation.
PROs appear to have a key role in the HTA processes; however,
the extent to which PROs are used outside of cost-utility analysis
is unclear. HTA trends are increasingly present in LatAm, with
three countries now using HTA explicitly to make coverage
decisions in their public subsystem (Brazil, Colombia, and Méx-
ico). Health utility measures, a subset of PROs, are a key
component of the HTA process and are used to calculate
quality-adjusted life-years, the metric value of interventions in
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available to generate health utilities, emphasis has been placed
on the use of the EQ-5D, a measure that has subsequently
become one of the most widely used PROs worldwide. EQ-5D
health valuation sets are available for Argentina, Chile, and
Brazil, and there is also a universal set that is based on Hispanics
living in the United States. It is expected that new value sets will
be developed and countries such as Colombia and México are
likely to lead this trend given the presence of a formal HTA
system. Guidelines for economic evaluation in LatAM should also
broadly reﬂect different options to health utility valuation.
Research should be encouraged into alternative sources of health
utility data collection, and HTA agencies should engage in a
multistakeholder dialogue about the value of PROs in this
process. This dialogue should expand beyond health utility
generation, as HTA agencies worldwide are advancing toward a
more comprehensive use of PROs in the health technologies
assessment and appraisal process. To fully understand the value
of PRO evidence in the HTA process, future studies should initiate
a systematic review of the HTA literature and qualitative dis-
cussion with HTA stakeholders.Conclusions
In this article, an overview of PROs and their application in LatAm
together with challenges and a suggested agenda moving forward
were presented. There is value in using PROs to explore the
outcomes of health interventions, and also to enrich population
and individual decision making in LatAm. Additional efforts
should concentrate on a systematic review of the apparently vast
PRO literature in LatAm, as well as highlighting additional
opportunities and challenges, including ethics committees eval-
uation of PRO use in observational research as well as regulatory
approaches to PROs in LatAm.
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